Literature DB >> 25245581

Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.

L Karlsson1, A-L Zackrisson2, M Josefsson3, B Carlsson4, H Green5, F C Kugelberg5.   

Abstract

We investigated whether polymorphisms in the CYP2D6 and CYP2C19 genes influence the metabolic ratios and enantiomeric S/R ratios of venlafaxine (VEN) and its metabolites O-desmethylvenlafaxine (ODV), N-desmethylvenlafaxine (NDV) and N,O-didesmethylvenlafaxine (DDV) in blood from forensic autopsy cases. In all, 94 postmortem cases found positive for VEN during toxicological screening were included. The CYP2D6 genotype was shown to significantly influence the ODV/VEN (P=0.003), DDV/NDV (P=0.010) and DDV/ODV (P=0.034) ratios. The DDV/ODV (P=0.013) and DDV/VEN (P=0.021) ratios were significantly influenced by the CYP2C19 genotype. The S/R ratios of VEN were significantly influenced by both CYP2D6 and CYP2C19 genotypes. CYP2D6 poor metabolizers (PMs) had lower S/R VEN ratios and CYP2C19 PMs had high S/R ratios of VEN in comparison. Our results show that the CYP2D6 genotype influences the O-demethylation whereas CYP2C19 influences the N-demethylation of VEN and its metabolites. In addition, we show a stereoselective metabolism where CYP2D6 favours the R-enantiomer whereas CYP2C19 favours the S-enantiomer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245581     DOI: 10.1038/tpj.2014.50

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  36 in total

1.  High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases.

Authors:  A L Zackrisson; B Lindblom; J Ahlner
Journal:  Clin Pharmacol Ther       Date:  2009-11-11       Impact factor: 6.875

Review 2.  PharmGKB summary: venlafaxine pathway.

Authors:  Katrin Sangkuhl; Julia C Stingl; Miia Turpeinen; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-01       Impact factor: 2.089

3.  O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.

Authors:  S M Fogelman; J Schmider; K Venkatakrishnan; L L von Moltke; J S Harmatz; R I Shader; D J Greenblatt
Journal:  Neuropsychopharmacology       Date:  1999-05       Impact factor: 7.853

Review 4.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

5.  Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative.

Authors:  E A Muth; J T Haskins; J A Moyer; G E Husbands; S T Nielsen; E B Sigg
Journal:  Biochem Pharmacol       Date:  1986-12-15       Impact factor: 5.858

6.  Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distributions.

Authors:  A L Zackrisson; P Holmgren; A B Gladh; J Ahlner; B Lindblom
Journal:  Eur J Clin Pharmacol       Date:  2004-09-02       Impact factor: 2.953

Review 7.  Venlafaxine: a heterocyclic antidepressant.

Authors:  V L Ellingrod; P J Perry
Journal:  Am J Hosp Pharm       Date:  1994-12-15

8.  Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.

Authors:  Chin B Eap; Etienne Lessard; Pierre Baumann; Marlyse Brawand-Amey; Marie-Andrée Yessine; Gilles O'Hara; Jacques Turgeon
Journal:  Pharmacogenetics       Date:  2003-01

9.  Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing.

Authors:  Anna-Lena Zackrisson; Bertil Lindblom
Journal:  Eur J Clin Pharmacol       Date:  2003-09-06       Impact factor: 2.953

10.  Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.

Authors:  M L Dahl; G Tybring; C E Elwin; C Alm; K Andreasson; M Gyllenpalm; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1994-08       Impact factor: 6.875

View more
  2 in total

1.  Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.

Authors:  Maxim Kuzin; Georgios Schoretsanitis; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Michael Paulzen
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

2.  Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer.

Authors:  Sofia Garcia; Michael Schuh; Anvir Cheema; Herjot Atwal; Paldeep S Atwal
Journal:  Case Rep Genet       Date:  2017-10-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.